Respiro Diagnostics secures £1M to advance lung diagnostics
Respiro Diagnostics, a UK-based startup developing breath-based diagnostics for lungdiseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital. Respiro Diagnostics is developing a breath-based diagnostic platform that analyses DNA, RNA and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases.
Key Takeaways
- Healthtech Respiro Diagnostics secures £1M to advance lung diagnostics Respiro Diagnostics is developing a breath-based diagnostic platform that analyses DNA, RNA and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases.
Tamara Djurickovic 1 hour ago Share Share Send email Copy link Respiro Diagnostics , a UK-based startup developing breath-based diagnostics for lung diseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital .
- Founded by Alison Quinn and Dr Theo Issitt , Respiro is developing a non-invasive liquid biopsy platform that uses exhaled breath to detect lung cancer and other respiratory diseases.
The company's technology combines a proprietary breath collection device with laboratory methods that analyse DNA, RNA and proteins captured from breath samples, providing an alternative to invasive tissue biopsies and blood-based liquid biopsies.
- According to the company, this approach could support earlier diagnosis and provide additional information to guide treatment decisions.
Our vision is simple: that one day, a breath sample is all it takes to know what's happening in your lungs - early, while there's still time to act, said Alison Quinn, CEO and co-founder of Respiro Diagnostics.
- The company is also evaluating potential applications of its platform in other respiratory conditions, including pulmonary hypertension and asthma.
The funding will support Respiro's clinical research and the continued development of its breath collection device and laboratory platform as the company advances towards clinical validation.
- What would you like us to deliver to you?
Stats & Key Facts
- #Respiro Diagnostics, a UK-based startup developing breath-based diagnostics for lungdiseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital.
- #Tamara Djurickovic 1 hour ago Share Share Send email Copy link Respiro Diagnostics , a UK-based startup developing breath-based diagnostics for lung diseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital .
Respiro Diagnostics is developing a breath-based diagnostic platform that analyses DNA, RNA and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases. Healthtech Respiro Diagnostics secures £1M to advance lung diagnostics Respiro Diagnostics is developing a breath-based diagnostic platform that analyses DNA, RNA and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases. Tamara Djurickovic 1 hour ago Share Share Send email Copy link Respiro Diagnostics , a UK-based startup developing breath-based diagnostics for lung diseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital .
The round also included participation from Amadeus Capital Partners, the Conception X Angel Syndicate, KQ Labs through the Francis Crick Institute, strategic angel investors and Innovate UK. Founded by Alison Quinn and Dr Theo Issitt , Respiro is developing a non-invasive liquid biopsy platform that uses exhaled breath to detect lung cancer and other respiratory diseases. The company's technology combines a proprietary breath collection device with laboratory methods that analyse DNA, RNA and proteins captured from breath samples, providing an alternative to invasive tissue biopsies and blood-based liquid biopsies.
Respiro's platform is being developed as a non-invasive alternative to existing diagnostic methods for lung diseases. Unlike tissue biopsies, which require invasive procedures, the technology analyses biological material collected directly from exhaled breath, including DNA, RNA and proteins. According to the company, this approach could support earlier diagnosis and provide additional information to guide treatment decisions.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation